Pieris Pharmaceuticals, Inc. (PIRS)

11.68 -0.03 (-0.26%) At close: 04:00PM EDT

Pieris Pharmaceuticals, Inc.

225 Franklin Street
26th Floor
Boston, MA 02110
United States
857 246 8998
https://www.pieris.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 46

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Stephen S. Yoder J.D.	CEO, President & Director	774.72k	N/A	1976
Mr. Thomas Bures	Senior VP, CFO & Treasurer	499.38k	N/A	1975
Maria Kelman	Executive Director of Investor Relations	N/A	N/A	N/A
Dr. Shane Olwill Ph.D.	Senior VP & Chief Development Officer	N/A	N/A	1976
Mr. Prompong Chaikul	Chief Supply Chain Officer	N/A	N/A	1987
Dr. Florian Witte Ph.D.	VP and Head of Alliance Management & Early Project Leadership	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.

Corporate governance

Pieris Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.